Cholesterol drug shows promise in preventing colon cancer for colitis patients

NCT ID NCT04767984

Ongoing Prevention Sponsor: Northwestern University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether atorvastatin, a widely used cholesterol medication, can reduce the risk of colon cancer in people with long-standing ulcerative colitis who carry a specific genetic mutation (P53). About 42 participants will take either atorvastatin or a placebo for a period, and researchers will measure changes in colon tissue samples to see if the drug lowers cancer-related markers. The goal is to find a safe, affordable way to prevent cancer in this high-risk group.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLORECTAL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal carcinoma colorectal neoplasm ulcerative colitis colorectal cancer prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COLORECTAL CARCINOMA ULCERATIVE COLITIS

Contacts and locations

Locations

Northwestern University

Chicago, Illinois, 60611, United States
University of Chicago Comprehensive Cancer Center

Chicago, Illinois, 60637, United States
University of Kansas Cancer Center

Kansas City, Kansas, 66160, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.